Astringent Powder, For Solution
NDC 63561-0178
Product Information
Astringent (calcium acetate monohydrate and aluminum sulfate tetradecahydrate) is a OTC MONOGRAPH DRUG-approved product labeled by Granulation Technology, Inc.. This medication is typically used as a blood coagulation factor [epc]. It is supplied as a white powder, for solution for topical administration. This product entry covers the primary NDC 63561-0178 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 63561-0178?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CALCIUM ACETATE MONOHYDRATE (UNII: 7ZA48GIM5H)
- CALCIUM CATION (UNII: 2M83C4R6ZB) (Active Moiety)
- ALUMINUM SULFATE TETRADECAHYDRATE (UNII: E3UT66504P)
- ALUMINUM CATION (UNII: 3XHB1D032B) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MALTODEXTRIN (UNII: 7CVR7L4A2D)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1250234 - aluminum sulfate 1347 MG / calcium acetate 952 MG in 160 ML Topical Solution
- RxCUI: 1250234 - aluminum sulfate 8.42 MG/ML / calcium acetate 5.95 MG/ML Topical Solution
- RxCUI: 1250234 - (3 Packets (aluminum sulfate 1347 MG Powder / calcium acetate 952 MG Powder)) per 16 OZ Topical Solution
- RxCUI: 1250234 - aluminum sulfate 1347 MG / calcium acetate 952 MG per 160 ML Topical Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.